A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Trial details
- Registry ID
- NCT06709014
- Drugs studied
- buntanetap/posiphen
TrialRedline tracks 5 clinical trials sponsored by Annovis Bio Inc.: 2 Phase 3, 3 Phase 2 / 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADNCT06709014 | buntanetap/posiphen | Active not recruiting | 2027-12Estimated |
| A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989 | buntanetap/posiphen | Completed | 2023-12-04Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Buntanetap in Participants With PDNCT07284784 | buntanetap/posiphen | Recruiting | 2029-09Estimated |
| An Open-label Long-term Safety Study of Buntanetap in Participants With ADNCT07757204 | buntanetap/posiphen | Not yet recruiting | 2030-02-21Estimated |
| A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADNCT05686044 | Buntanetap/Posiphen | Completed | 2024-02-13Actual |
Names as written in the registry records.
NCT06709014 · Annovis Bio Inc.
Before: Estimated. After: Actual.
Before: 760 participants (planned). After: 861 participants (actual).
NCT06709014 · Annovis Bio Inc.
Before: Recruiting. After: Active not recruiting.
NCT07284784 · Annovis Bio Inc.
Before: Not yet recruiting. After: Recruiting.